Rapid Detection of SARS-CoV-2 RNA Using Reverse Transcription Recombinase Polymerase Amplification (RT-RPA) with Lateral Flow for N-Protein Gene and Variant-Specific Deletion-Insertion Mutation in S-Protein Gene.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
26 05 2023
Historique:
received: 14 04 2023
revised: 21 05 2023
accepted: 24 05 2023
medline: 29 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Rapid molecular testing for severe acute respiratory coronavirus 2 (SARS-CoV-2) variants may contribute to the development of public health measures, particularly in resource-limited areas. Reverse transcription recombinase polymerase amplification using a lateral flow assay (RT-RPA-LF) allows rapid RNA detection without thermal cyclers. In this study, we developed two assays to detect SARS-CoV-2 nucleocapsid (N) gene and Omicron BA.1 spike (S) gene-specific deletion-insertion mutations (del211/ins214). Both tests had a detection limit of 10 copies/µL in vitro and the detection time was approximately 35 min from incubation to detection. The sensitivities of SARS-CoV-2 (N) RT-RPA-LF by viral load categories were 100% for clinical samples with high (>9015.7 copies/µL, cycle quantification (Cq): < 25) and moderate (385.5-9015.7 copies/µL, Cq: 25-29.9) viral load, 83.3% for low (16.5-385.5 copies/µL, Cq: 30-34.9), and 14.3% for very low (<16.5 copies/µL, Cq: 35-40). The sensitivities of the Omicron BA.1 (S) RT-RPA-LF were 94.9%, 78%, 23.8%, and 0%, respectively, and the specificity against non-BA.1 SARS-CoV-2-positive samples was 96%. The assays seemed more sensitive than rapid antigen detection in moderate viral load samples. Although implementation in resource-limited settings requires additional improvements, deletion-insertion mutations were successfully detected by the RT-RPA-LF technique.

Identifiants

pubmed: 37376555
pii: v15061254
doi: 10.3390/v15061254
pmc: PMC10302577
pii:
doi:

Substances chimiques

Recombinases 0
RNA, Viral 0
Nucleotidyltransferases EC 2.7.7.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nature. 2021 Dec;600(7887):21
pubmed: 34824381
Anal Biochem. 2018 Apr 1;546:72-77
pubmed: 29408177
J Virol Methods. 2021 Oct;296:114227
pubmed: 34224752
Viruses. 2020 Dec 10;12(12):
pubmed: 33322035
Med Microbiol Immunol. 2023 Feb;212(1):103-122
pubmed: 36583790
Nature. 2019 Feb;566(7742):120-125
pubmed: 30700913
Curr Pharm Des. 2006;12(15):1811-25
pubmed: 16724949
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583765
Int J Biol Sci. 2022 Jul 11;18(12):4610-4617
pubmed: 35874951
Nature. 2023 Feb;614(7948):521-529
pubmed: 36535326
EMBO Rep. 2022 Oct 6;23(10):e54322
pubmed: 35999696
Int J Infect Dis. 2022 Jan;114:105-111
pubmed: 34758392
Anal Chem. 2021 Feb 2;93(4):2627-2634
pubmed: 33471510
Sci Rep. 2021 Apr 27;11(1):9026
pubmed: 33907239
Nat Commun. 2022 Nov 16;13(1):7003
pubmed: 36385137
Sci Transl Med. 2020 Aug 12;12(556):
pubmed: 32719001
J Clin Microbiol. 2021 Jul 19;59(8):e0092621
pubmed: 34011523
Lancet Infect Dis. 2023 Mar;23(3):280-281
pubmed: 36736338
J Clin Virol. 2021 Aug;141:104903
pubmed: 34182300
Sens Actuators B Chem. 2023 Apr 15;381:133433
pubmed: 36743821
PLoS One. 2021 Jan 6;16(1):e0245164
pubmed: 33406112
Jpn J Infect Dis. 2020 Jul 22;73(4):304-307
pubmed: 32074516
Front Bioeng Biotechnol. 2022 Jan 21;9:800104
pubmed: 35127671
Biomed Pharmacother. 2022 Oct;154:113522
pubmed: 36030585
PLoS Biol. 2006 Jul;4(7):e204
pubmed: 16756388
Int J Mol Sci. 2023 Jan 23;24(3):
pubmed: 36768588
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
World J Hepatol. 2014 Dec 27;6(12):916-22
pubmed: 25544878
Exp Biol Med (Maywood). 2021 Feb;246(4):400-405
pubmed: 33153299
Sci Rep. 2021 Jul 16;11(1):14604
pubmed: 34272449
Emerg Microbes Infect. 2022 Dec;11(1):978-987
pubmed: 35293849
BMC Bioinformatics. 2012 Jun 18;13:134
pubmed: 22708584
MedComm (2020). 2023 Mar 15;4(2):e239
pubmed: 36938325
J Transl Med. 2021 Feb 16;19(1):74
pubmed: 33593370
Hepatology. 1992 Aug;16(2):293-9
pubmed: 1322348
Eur J Intern Med. 2023 Jul;113:13-15
pubmed: 37087389
Genome Biol. 2021 Jun 3;22(1):169
pubmed: 34082799
Int J Infect Dis. 2023 Feb;127:56-62
pubmed: 36455809
J Clin Virol. 2021 Oct;143:104969
pubmed: 34509927
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Saudi J Biol Sci. 2022 Nov;29(11):103465
pubmed: 36186678
Diagnostics (Basel). 2022 May 19;12(5):
pubmed: 35626420
Int J Mol Sci. 2022 Nov 15;23(22):
pubmed: 36430586
Nat Mater. 2021 May;20(5):593-605
pubmed: 33589798
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Lab Chip. 2021 May 18;21(10):2019-2026
pubmed: 34008614
Biotechnol Adv. 2022 Nov;60:108010
pubmed: 35738511
Anal Chem. 2022 Dec 13;94(49):17151-17159
pubmed: 36459151
Microbiol Spectr. 2022 Aug 31;10(4):e0073622
pubmed: 35758686
Viruses. 2023 Jan 05;15(1):
pubmed: 36680207

Auteurs

Jose L Malaga (JL)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

Monica J Pajuelo (MJ)

Laboratorio Microbiología Molecular, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.

Michiko Okamoto (M)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

Emmanuel Kagning Tsinda (EK)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
Center for Biomedical Innovation, Sinskey Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Kanako Otani (K)

National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Pablo Tsukayama (P)

Laboratorio de Genómica Microbiana, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.

Lucero Mascaro (L)

Laboratorio Microbiología Molecular, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.

Diego Cuicapuza (D)

Laboratorio de Genómica Microbiana, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.

Masamichi Katsumi (M)

Sendai City Institute of Health, Sendai 984-0002, Japan.
Sendai Shirayuri Women's College, Sendai 981-3107, Japan.

Kazuhisa Kawamura (K)

Kawamura Children's Clinic, Sendai 981-0907, Japan.

Hidekazu Nishimura (H)

Virus Research Center, Clinical Research Division, Sendai Medical Center, Sendai 983-8520, Japan.

Akie Sakagami (A)

Department of Microbiology, Miyagi Prefectural Institute of Public Health and Environment, Sendai 983-0836, Japan.

Yo Ueki (Y)

Department of Microbiology, Miyagi Prefectural Institute of Public Health and Environment, Sendai 983-0836, Japan.

Suguru Omiya (S)

Virus Research Center, Clinical Research Division, Sendai Medical Center, Sendai 983-8520, Japan.

Satoshi Okamoto (S)

Department of Clinical Laboratory, Tohoku Kosai Hospital, Sendai 980-0803, Japan.

Asami Nakayama (A)

Department of Laboratory Medicine, Tohoku University Hospital, Sendai 980-8574, Japan.

Shin-Ichi Fujimaki (SI)

Department of Laboratory Medicine, Tohoku University Hospital, Sendai 980-8574, Japan.

Chuyao Yu (C)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

Sikandar Azam (S)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

Eiichi Kodama (E)

International Research Institute of Disaster Science, Tohoku University, Sendai 980-8572, Japan.

Clyde Dapat (C)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.

Hitoshi Oshitani (H)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

Mayuko Saito (M)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH